New Delhi, Apr 9 (PTI) Strides Pharma Science on Tuesday said its subsidiary has received approval from the US health regulator to market a generic antidepressant medication.

The company's Singapore-based step-down wholly-owned subsidiary, Strides Pharma Global Pte Ltd, has received approval for Fluoxetine Tabs (10 and 20 mg) from the US Food & Drug Administration (USFDA), the drug firm said in a regulatory filing.

Also Read | BJP Foundation Day 2024 Date: Know the History and Significance of BJP Sthapna Diwas That Celebrates the Formation of the Bharatiya Janata Party.

The company's product is therapeutically equivalent to Eli Lilly's Prozac tablets.

As per IMS, Fluoxetine tablets have a market size of USD 23.9 million.

Also Read | AMC Raising Day 2024: Army Medical Corps Celebrates 260th Raising Day as They Live Up To The Corps Motto.

This approval further strengthens the company's presence in the Fluoxetine portfolio, complementing the existing approval of Fluoxetine capsules, which has a market size of USD106 million, the Bengaluru based firm said.

Fluoxetine is used for the treatment of major depressive disorder (MDD) and Obsessive Compulsive Disorder (OCD) among others.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)